Professor Olav Mella and Dr Øystein Fluge

Haukeland University, Bergen, Norway

Conference Speakers - Professor Olav Mella and Dr Øystein Fluge

Invest in ME Research is pleased to welcome back Professor Olav Mella and Dr Øystein Fluge to participate in the #BRMEC7 Colloquium and #IIMEC12 conference.
Professor Olav Mella and Dr Øystein Fluge

The research centre at Haukeland University Hospital in Bergen has been a focal point for raising hopes of finding treatments for ME since their discovery that an ME patient who was being treated for B-cell lymphoma had improved following their treatment with Rituximab.

At our 2011 Invest in ME international conference, these Norwegian cancer specialists announced strikingly successful results in their pilot study of the immunotherapy drug rituximab on ME/CFS patients. In that study [1] 67% of ME/CFS patients had moderate to major improvement, compared to only 13% of controls.

The pattern of response indicated that ME may have an autoimmune component because rituximab works by temporarily wiping out immune-system B cells, which are implicated in autoimmune disease.

These ground-breaking results gained international attention when the study was published.

Dr Fluge and Professor Mella have spoken at several of Invest in ME Research's International Colloquiums and Conferences.

Their approach to research into ME has been exemplary - full of integrity, science and empathy towards patients.
The latest news from their research was highlighted in an article from Kavli Fondet's web site (Kavli Fondet have been very generous in funding a great deal of the research into ME at Haukeland) - New study on pathological mechanisms in ME from Bergen research group

Dr Fluge and his team will be visiting Norwich in January 2017 to collaborate with the Norwich Centre of Excellence in planning of the UK rituximab trial - more info here.


Further Links

Return to Conference News